Patent Owner's Updated Mandatory Notices | Oct 17, 2025 | PAPER | PATENT OWNER |
Ex. 2003 - PhRMA Research Development Policy Framework (Sept. 2024) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2004 - Beauroyre (Abacum 6.25.2025) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2005 - CCRPS, Phase III Clinical Trials Definitive Guide & Case Studies (6.8.2025) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2006 - Fierce Healthcare (9.23.2011) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2009 - NIH-clinicaltrials.gov, Eli Lilly, A Study of Tirzepatide (6.26.2017) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2010 - Coskun et al. (Molecular Metabolism 2018) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2011 - Eli Lilly Q2 2016 Earnings Presentation | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2013 - Eli Lilly Press Release (10.4.2018) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2014 - Frias et al. (Lancet 2018) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2015 - Pharmaceutical Technology (10.5.2018) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2016 - Helfand (Fierce Pharma 10.8.2018) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2017 - Eli Lilly Press Release (12.9.2020) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2018 - Eli Lilly Press Release (2.17.2021) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2019 - Eli Lilly Press Release (6.25.2021) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2020 - Eli Lilly Press Release (6.21.2024) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2021 - Frias et al. (NEJM 2021) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2022 - Ludvik et al. (Lancet 2021) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2023 - Jastreboff et al. (NEJM 2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2024 - Wadden et al. (Nature Med. 2023) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2025 - Kolata (NY Times 4.28.2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2026 - Zoler (Medscape June 2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2027 - Rosenstock (Diabetes Care 2023) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2028 - Hosie (Business Insider 6.6.2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2029 - Chavda et al. (Molecules 2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2030 - Loftus (WSJ 4.3.2023) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2031 - Drug Discovery Development (6.3.2021) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2032 - Buntz (Drug, Discovery Dev. 4.28.2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2033 - Mullard (Nature Revs. Drug Discovery 5.20.2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2034 - Biochem PEG (5.20.2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2035 - Wang (Drug Design Dev. Therapy 2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2036 - Sainz (diaTribe Learn 9.21.2022) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2037 - Doctors Business Network (4.28.2025) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2038 - Buntz (Drug Discovery Dev. 10.16.2023) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2041 - Zacks Equity Rsch. (Nasdaq 12.10.2020) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2044 - FDA, Orange Book-Approved Drug Products With Therapeutic Equivalence Evaluations, Tirzepatide | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2049 - Eli Lilly - Tirzepatide Clinical Studies Listing (Clinicaltrials.gov) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2050 - Eli Lilly - Tirzepatide Non-NCT Clinical Trials (compilation) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2088 - Search Results from USP 9474780 File History | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2089 - WO2010071807A1 DiMarchi | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2090 - Eli Lilly Press Release (8.27.2024) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2091 - Eli Lilly Press Release (2.26.2025) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2092 - Eli Lilly Press Release (5.24.2024) | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Ex. 2094 - Belcher Pharmaceuticals - About Us | Oct 14, 2025 | EXHIBIT | PATENT OWNER |
Patent Owner's Discretionary Denial Brief | Oct 14, 2025 | PAPER | PATENT OWNER |
Notice: Power of Attorney | Aug 25, 2025 | PAPER | PATENT OWNER |
Notice: Mandatory Notice | Aug 25, 2025 | PAPER | PATENT OWNER |
NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE | Aug 12, 2025 | PAPER | BOARD |
EX1001-US Patent US9474780B2 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1002-Declaration Dr. Virginia Cornish | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1004-Prosecution History US Patent 9474780 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1005-International Search Report | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1006-Written Opinion | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1007-WO2011-119657 A1 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1008-WO2013-164483 A1 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1009-WO2006-097537 A2 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1010-WO2014-202727 A1 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1011-Article- Introduction to Peptide Synthesis | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1012-US Patent Application Publication | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1013-Article- Injection Drug Label(SAXENDA) | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1014-Article- Lehninger Principles of Biochemistry | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1015-Article- Hormones and their Actions Part 1 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1016-Article-Pyrrolsysine and Selencysteine | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1018-The synthesis of a tetrapeptide | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1019-Article- Synthetic Analogs of Oxytocin and the Vasopressins | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1020 - Keen_Human Insulin Produced | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1021 - Karten_Gonadotropin-releasing hormone | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1022 - Garay_Antibodies against polyethylene | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1023 - Knudsen_the therapeutic promise from animal models | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1024 - Ward_Peptide lipidation stabilizes structure | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1025 - Zhang_Converting peptides into drug leads | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1026-Article- Synthetic Molecular Evolution of Pore-Forming Peptides | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1027-Article-New Type of Synthetic peptide library | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1028 - Liu_Article-High-Througout Screening of One-Bead-One-Compound L | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1029-Article-GPCR structures in drug design | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1030-Reviews-The structure and function of the glucagon | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1031-Reviews-Teaching old receptors new tricks | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1032-Article-New insights into the role of Camp in the production and fun | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1033-Article-Functional Consequences of Glucagon | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1034-Article-Beta-Arrestin2 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1035-Oxyntomodulin Differentially Affects Glucago | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1036 - Sonoda_Article - B-Arrestin-1 mediates glucagon-like peptide-1 sig | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1037-Article-Structure of the human glucagon class BG-protein | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1038-Article-Mechanisms of peptide and nonpeptide ligand binding to Class | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1039-Article - Allosteric Modulators of Class B G-Protein | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1040-Article-GIP and GLP-1 two incretin hormones | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1041-Article-Further Purification of Polypeptide Demonstrating Enterogast | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1042-Article-Gastric Inhibitory Polypeptide Structure and Chromosomal | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1043-Article-Stimulation of Insulin Secretion | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1044-Article-Pancreatic- Polypeptide Glucagon and Insulin Secretion | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1045-Article_LUND Pancreatic preproglucagon cDNA contains two glucagon re | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1046-Article - The short half-life of glucagon | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1047-Article-Novel mechanism of actions | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1048-Kieffer_Article-Degradation of Glucose-Dependent Insulinotropic Poly | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1049-Article - High Potency Antagonists of the Pancreatic Glucagon | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1050-Article-Injection Drug label - (VICTOZA) | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1051-Article - Liraglutide_ A Review of the First Once -Daily GLP-1 Recep | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1052-Article - Liraglutide-A Once Daily Incretin Mimetic for the Treatmen | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1053-Article - Injection drug label (BYDUEREON) | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1054-Article - Injection Drug Label (BYETTA) | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1055-Article-Injection drug label (TRULICITY) | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1056-Article-Injection Drug Label (ADLYXIN) | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1057- Article -Injection Drug Label -(Ozempic) | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1058-Article - Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bod | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1059-Article- A new glucagon and GLP-1 Co-agonist eliminates obesity | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1060-Article - Glucagon-Like Peptide 1_Glucagon Receptor Dual Agonism Rev | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1061-Article-Unimolecular Dual Incretins maximize metabolic Benefits | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1062-Article - Crystal structure of Rhodospin_A G-Protein-Coupled Recepto | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1063-Article- Crystal Structure of the human B2 adrenergic G-Protein-coup | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1064 - Article-GPCR Network A large-scale collaboration | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1065-Article - Protein Data Bank | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1066-Article Biological Activities of Glucagon Like Peptide 1 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1067-Article - Structure-Activity Studies of Glucagon-like Peptide -1 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1068-Article - Glucagon-like Peptide-1 (GLP-1) | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1069-Article-Endoproteolysis by isolated membrane peptidases | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1070-Article-Clinical relevance of anti-exenatide antibodies | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1071-Article - Liraglutide Treatment is Associated with a low frequency | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1072- Doyle_C-terminal sequence | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1073- Simonsen_C-terminal Extension | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1074 - Tatarkiewicz_Article - A novel long-acting glucose-dependent | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1075 - WO2015-067715-A2 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1076 - Lorenz | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1078 - Karp - Textbook Excerpts | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1079 - Madsen_2007 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1080 - IPR2025-01024 Petition | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1082 - Runge | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1083 - Torekov | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1084 - Dr. Zhou Declaration | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1085 - Sunny Zhou CV 2025-07-16 | Aug 4, 2025 | EXHIBIT | PETITIONER |
EX1017 - WO2010011439A2 | Aug 4, 2025 | EXHIBIT | PETITIONER |
Notice: Power of Attorney | Aug 4, 2025 | PAPER | PETITIONER |
Petition: as filed | Aug 4, 2025 | PAPER | PETITIONER |